CO4480040A1 - Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2 - Google Patents
Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2Info
- Publication number
- CO4480040A1 CO4480040A1 CO95057860A CO95057860A CO4480040A1 CO 4480040 A1 CO4480040 A1 CO 4480040A1 CO 95057860 A CO95057860 A CO 95057860A CO 95057860 A CO95057860 A CO 95057860A CO 4480040 A1 CO4480040 A1 CO 4480040A1
- Authority
- CO
- Colombia
- Prior art keywords
- surface antigen
- phase
- cells
- extract
- purified
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 11
- 102000036639 antigens Human genes 0.000 title abstract 11
- 108091007433 antigens Proteins 0.000 title abstract 11
- 208000002672 hepatitis B Diseases 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title abstract 2
- 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 238000004440 column chromatography Methods 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000001641 gel filtration chromatography Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 239000002210 silicon-based material Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
UN PROCESO DE PURIFICACIONES ANTIGENO DE SUPERFI- CIE DE HEPATITIS B VIRAL QUE COMPRENDE PEPTIDO PRES2 DE CELULAS DE UN MICROORGANISMO RECOMBINAN- TE, QUE COMPRENDE LA FASE DE DEGRADACION DE LAS CELULAS EMPLEANDO UN BUFFER QUE CONTIENE UNA SAL CAOTROPICA PARA OBTENER EL HOMOGENIZADO CELULAR. EL PROCESO SEGUN LA FASE 1 EN DONDE LA SAL CAOTRO- FICA SE SELECCIONA DE UN GRUPO QUE CONSISTE EN: TIOSIONATO DE SODIO, TIOSIONATO DE POTASIO, TIO- SIONATO DE AMONIO Y CLORURO DE GUANIDA Y UREA. EL PROCESO EN EL NUMERAL 1, MEDIANTE LA OBTENCION DE LA CONCENTRACION DE UNA SAL CAOTROFICA EN EL BUF- FER CON UN RANGO DE 1 A 8 M. EL PROCESO EN LA FA- SE 1, QUE ADEMAS COMPRENDE LAS FASES SIGUIENTES: a. ANADIR SURFACTANTE AL HOMOGENIZADO CELULAR AL EXTRACTO DE ANTIGENO DE SUPERFICIE DE LA MEMBRANA CELULAR DE LAS CELULAS. b. AUMENTO DE LA SOLUBI- LIDAD Y PROMOCION DE FORMACION DE PARTICULAS DE ANTIGENO DE SUPERFICIE EN EL LISTADO OBTENIDO EN LA FASE A ALCALINIZANDO EL EXTRACTO. c. PRECIPITACION Y REMOCION DE LOS RESTOS CELULA- RES, LIPIDOS Y PROTEINAS CONTAMINANTES DEL ESTRATO TRATADO EN LA FASE B ACIDIFICANDO Y LUEGO CENTRI- FUGANDO EL EXTRACTO, PARA OBTENER UNA SOLUCION QUE CONTENGA ANTIGENO DE SUPERFICIE. d. LUEGO SE EN- TRA EN CONTACTO CON LA SOLUCION OBTENIDA EN LA FA- SE c CON MATERIAL DE SILICE QUE ABSORBE EL ANTIGE- NO DE SUPERFICIE EN EL, Y SE LAVAN LAS PROTEINAS CONTAMINANTES, Y SE DESABSORBE EL ANTIGENO DE SU- PERFICIE DEL MATERIAL DE SILICE EMPLEANDO UN BUF- FER QUE SE OBTIENE DE UNA FRACCION DEL ANTIGENO DE SUPERFICIE PURIFICADO. e. SE SOMETE LA FRACCION DEL ANTIGENO DE SUPERFICIE PURIFICADO OBTENIDO EN LA FASE D, A UNA CROMATOGRAFIA DE COLUMNA HIDROFO- BICA, PARA OBTENER FRACCIONES QUE CONTENGAN EL AN- TIGENO DE SUPERFICIE Y f. SE PURIFICAN LAS FRACCIONES OBTENIDAS EN LA FASE E, CON UN GEL ME- DIANTE CROMATOGRAFIA DE FILTRACION, PARA OBTENER EL ANTIGENO DE SUPERFICIE EN FORMA PURA. FIGURA 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR19940033594 | 1994-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4480040A1 true CO4480040A1 (es) | 1997-07-09 |
Family
ID=19400952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO95057860A CO4480040A1 (es) | 1994-12-10 | 1995-12-07 | Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6362320B1 (es) |
| EP (1) | EP0716094B1 (es) |
| KR (1) | KR960023066A (es) |
| CN (1) | CN1057532C (es) |
| AR (1) | AR002006A1 (es) |
| AT (1) | ATE264341T1 (es) |
| BG (1) | BG63699B1 (es) |
| BR (1) | BR9505739A (es) |
| CA (1) | CA2164672C (es) |
| CO (1) | CO4480040A1 (es) |
| CZ (1) | CZ291024B6 (es) |
| DE (1) | DE69532878T2 (es) |
| DK (1) | DK0716094T3 (es) |
| ES (1) | ES2217272T3 (es) |
| JO (1) | JO1885B1 (es) |
| PE (1) | PE56396A1 (es) |
| PL (1) | PL182103B1 (es) |
| PT (1) | PT716094E (es) |
| RO (1) | RO113308B1 (es) |
| RU (1) | RU2122430C1 (es) |
| TR (1) | TR199501557A2 (es) |
| UY (1) | UY24112A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
| KR100405174B1 (ko) * | 2001-02-02 | 2003-11-12 | 씨제이 주식회사 | 재조합 β형 간염바이러스 표면항원의 정제방법 |
| CN1997895A (zh) * | 2004-05-19 | 2007-07-11 | 株式会社先端生命科学研究所 | 乙型肝炎病毒的检测方法 |
| GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| KR100948127B1 (ko) * | 2007-06-27 | 2010-03-18 | 주식회사 중앙백신연구소 | 복합호흡기 질환 돼지의 조직유제를 함유하는 백신 조성물 |
| KR102196230B1 (ko) | 2012-09-17 | 2020-12-29 | 더블유.알. 그레이스 앤드 캄파니-콘. | 크로마토그래피 매질 및 장치 |
| FR2997222B1 (fr) * | 2012-10-19 | 2015-01-16 | Alstom Technology Ltd | Dispositif d'etablissement et/ou de coupure de courant a contacts permanents a usure reduite |
| CN107847907A (zh) | 2014-05-02 | 2018-03-27 | 格雷斯公司 | 官能化载体材料以及制备和使用官能化载体材料的方法 |
| KR102566292B1 (ko) | 2015-06-05 | 2023-08-10 | 더블유.알. 그레이스 앤드 캄파니-콘. | 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340926A (en) * | 1983-03-25 | 1994-08-23 | Celltech, Limited | Process for the recovery of recombinantly produced protein from insoluble aggregate |
| US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
| EP0291146B1 (en) * | 1987-03-09 | 1993-09-01 | Merck & Co. Inc. | Purification of recombinant hepatitis b surface antigen |
| EP0310178A1 (en) * | 1987-09-30 | 1989-04-05 | Merck & Co. Inc. | Recovery of pres2+S antigen |
| EP0314240A3 (en) * | 1987-10-26 | 1990-03-28 | Merck & Co. Inc. | Process for purifying recombinant hepatitis antigens |
| US5004688A (en) * | 1988-04-15 | 1991-04-02 | Phillips Petroleum Company | Purification of hepatitis proteins |
| US5030720A (en) * | 1988-09-01 | 1991-07-09 | Merck & Co., Inc. | Pres2+S hepatitis B vaccine derived from plasma |
| EP0384058A1 (en) * | 1989-02-09 | 1990-08-29 | Development Center For Biotechnology | Isolation of hepatitis B surface antigen from transformed yeast cells |
| CU22290A1 (es) * | 1990-10-08 | 1995-01-31 | Cigb | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
-
1995
- 1995-11-29 KR KR1019950044795A patent/KR960023066A/ko not_active IP Right Cessation
- 1995-12-07 JO JO19951885A patent/JO1885B1/en active
- 1995-12-07 PE PE1995286655A patent/PE56396A1/es not_active Application Discontinuation
- 1995-12-07 CA CA002164672A patent/CA2164672C/en not_active Expired - Fee Related
- 1995-12-07 CO CO95057860A patent/CO4480040A1/es unknown
- 1995-12-08 AT AT95119383T patent/ATE264341T1/de not_active IP Right Cessation
- 1995-12-08 CZ CZ19953247A patent/CZ291024B6/cs not_active IP Right Cessation
- 1995-12-08 RU RU95120587A patent/RU2122430C1/ru not_active IP Right Cessation
- 1995-12-08 DK DK95119383T patent/DK0716094T3/da active
- 1995-12-08 RO RO95-02141A patent/RO113308B1/ro unknown
- 1995-12-08 PT PT95119383T patent/PT716094E/pt unknown
- 1995-12-08 ES ES95119383T patent/ES2217272T3/es not_active Expired - Lifetime
- 1995-12-08 PL PL95311735A patent/PL182103B1/pl not_active IP Right Cessation
- 1995-12-08 BG BG100212A patent/BG63699B1/bg unknown
- 1995-12-08 EP EP95119383A patent/EP0716094B1/en not_active Expired - Lifetime
- 1995-12-08 DE DE69532878T patent/DE69532878T2/de not_active Expired - Fee Related
- 1995-12-11 AR ARP950100498A patent/AR002006A1/es active IP Right Grant
- 1995-12-11 CN CN95120408A patent/CN1057532C/zh not_active Expired - Fee Related
- 1995-12-11 UY UY24112A patent/UY24112A1/es not_active IP Right Cessation
- 1995-12-11 TR TR95/01557A patent/TR199501557A2/xx unknown
- 1995-12-11 BR BR9505739A patent/BR9505739A/pt not_active Application Discontinuation
-
1999
- 1999-11-02 US US09/432,300 patent/US6362320B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT716094E (pt) | 2004-08-31 |
| BG100212A (bg) | 1996-12-31 |
| KR0177254B1 (es) | 1999-04-01 |
| RU2122430C1 (ru) | 1998-11-27 |
| TR199501557A2 (tr) | 1997-03-21 |
| DK0716094T3 (da) | 2004-07-26 |
| UY24112A1 (es) | 1996-05-10 |
| CZ324795A3 (en) | 1996-06-12 |
| BR9505739A (pt) | 1997-12-23 |
| DE69532878D1 (de) | 2004-05-19 |
| CA2164672A1 (en) | 1996-06-11 |
| EP0716094B1 (en) | 2004-04-14 |
| BG63699B1 (bg) | 2002-09-30 |
| AR002006A1 (es) | 1998-01-07 |
| EP0716094A1 (en) | 1996-06-12 |
| DE69532878T2 (de) | 2005-06-09 |
| CA2164672C (en) | 2004-06-22 |
| PL182103B1 (pl) | 2001-11-30 |
| JO1885B1 (en) | 1997-12-15 |
| RO113308B1 (ro) | 1998-06-30 |
| PL311735A1 (en) | 1996-06-24 |
| KR960023066A (ko) | 1996-07-18 |
| ES2217272T3 (es) | 2004-11-01 |
| ATE264341T1 (de) | 2004-04-15 |
| US6362320B1 (en) | 2002-03-26 |
| CN1132211A (zh) | 1996-10-02 |
| CN1057532C (zh) | 2000-10-18 |
| CZ291024B6 (cs) | 2002-12-11 |
| PE56396A1 (es) | 1996-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0126767B1 (ko) | 계면활성제를 이용한 단백질 회수방법 | |
| Wagner et al. | Structural proteins of vesicular stomatitis viruses | |
| KR860008276A (ko) | 단백질이 생성된 배양기로 부터 그것을 추출, 정제하는 방법 | |
| PT893450E (pt) | Metodo cromatografico para purificacao de elevado rendimento e inactivacao viral de anticorpos | |
| PT85935B (pt) | Processo para a extraccao de proteinas lipofilicas produzidas por pichia | |
| CO4480040A1 (es) | Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2 | |
| FR2372841A1 (fr) | Gamma-globuline injectable par voie intraveineuse | |
| Allan et al. | Isolation and composition of human thymocyte plasma membrane | |
| DE69221225D1 (de) | Verfahren zum Reinigen von Hepatits-A-Virus (HAV), so gereinigter Virus und Impfstoffzusammensetzungen, die ihn enthalten | |
| DK0504318T3 (da) | Udvinding af Bt-endotoxinprotein fra lyserede celleblandinger | |
| Rao et al. | Purification of functional subunits of the eighth component of human complement (C8) under nondenaturing conditions | |
| Stubblefield et al. | Biochemical and morphological studies of partially purified Chinese hamster chromosomes | |
| JPS59231097A (ja) | 均質ヒト免疫インターフェロンサブタイプ２１ｋおよびその製造法 | |
| Qureshi et al. | Group B arbovirus structural and nonstructural antigens I. Serological identification of Saint Louis encephalitis virus soluble antigens | |
| Pal et al. | Pardaxin, a hydrophobic toxin of the Red Sea flatfish, disassembles the intact membrane of vesicular stomatitis virus. | |
| Yamamoto et al. | Specific release of the extrinsic 18-kDa protein from spinach Photosystem-II particles by the treatment with NaCl and methanol and its application for large-scale purification of the three extrinsic proteins of Photosystem II without chromatography | |
| SE7906137L (sv) | Rening av faktor viii | |
| RU93038775A (ru) | Способ получения фукоксантина | |
| US4681931A (en) | Process for the isolation and purification of alpha-interferons | |
| KR970073604A (ko) | 재조합 b형 간염 표면 항원의 정제방법 | |
| de Jong et al. | Purification of inhibin from bovine follicular fluid (BFF) | |
| Rubinstein et al. | Isolation of a cytoplasmic polyhedrosis virus by physical and immunological techniques | |
| Casale et al. | Crystallization of the Fab from a human monoclonal antibody against gp 41 of human immunodeficiency virus type I | |
| Kongsvik et al. | Subfractionation of CsCI-purified H-1 parvovirus on metrizamide gradients | |
| Godbout et al. | Isolation of “inhibin” from porcine follicular fluid following preparative polyacrylamide gradient gel electrophoresis |